Isaksson Marléne, Bruze Magnus
Department of Occupational and Environmental Dermatology, Malmö University Hospital, Sweden.
J Am Acad Dermatol. 2002 Jun;46(6):880-5. doi: 10.1067/mjd.2002.120464.
Up to 5% of patients with dermatitis who are consecutively patch tested are allergic to one or more corticosteroids. However, few reports of allergic mucosal and skin symptoms in patients with asthma and rhinitis caused by inhaled corticosteroids exist.
Our purpose was to determine whether inhalation of budesonide would result in reactivation of patch test reactions caused by budesonide.
The study, which was randomized, double-blind, and placebo-controlled, was ethically reviewed by the Medical Faculty, University of Lund, Sweden. Fifteen nonasthmatic patients who were initially given a diagnosis of budesonide hypersensitivity on patch testing from less than 1 up to 8 years before the study were provoked with budesonide or placebo by inhalation 6 weeks after they had been patch tested with budesonide, its R and S diastereomers, and potentially cross-reacting substances. Lung function was studied by using spirometry and repeated peak expiratory flow measurements.
In 4 of 7 patients who inhaled budesonide, reactivation of previously positive patch test reactions was noted within 24 hours, in contrast to 0 of 8 patients who inhaled placebo (P =.026). No adverse pulmonary responses could be detected.
This study shows that allergic skin reactions may occur in patients with contact allergy to budesonide when inhaled forms of the drug are used.
在连续进行斑贴试验的皮炎患者中,高达5%的患者对一种或多种皮质类固醇过敏。然而,关于吸入性皮质类固醇导致哮喘和鼻炎患者出现过敏性黏膜和皮肤症状的报道很少。
我们的目的是确定吸入布地奈德是否会导致由布地奈德引起的斑贴试验反应重新激活。
这项随机、双盲、安慰剂对照研究经瑞典隆德大学医学院进行了伦理审查。15名非哮喘患者在研究前不到1至8年的斑贴试验中最初被诊断为布地奈德过敏,在使用布地奈德、其R和S非对映异构体以及可能发生交叉反应的物质进行斑贴试验6周后,通过吸入布地奈德或安慰剂进行激发试验。通过肺活量测定和重复的呼气峰值流量测量来研究肺功能。
吸入布地奈德的7名患者中有4名在24小时内出现先前阳性斑贴试验反应的重新激活,而吸入安慰剂的8名患者中无1例出现这种情况(P = 0.026)。未检测到不良肺部反应。
本研究表明,对布地奈德有接触性过敏的患者在使用吸入剂型药物时可能会发生过敏性皮肤反应。